Varlilumab Active and Well-tolerated in Solid Tumors

Share this content:
This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.
This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.

The first-in-class anti-CD27 antibody varlilumab demonstrated clinical activity among and was well-tolerated by patients with solid tumors, according to a study published in the Journal of Clinical Oncology.1

Varlilumab is being evaluated in an open-label, phase 1, dose-escalation trial among patients with solid and hematologic tumors. This analysis includes patients with solid tumors including renal cell carcinoma (RCC), hormone-refractory prostate cancer, ovarian cancer, colorectal adenocarcinoma (CRC), and non–small cell lung cancer.

The study enrolled 56 patients with stage IV disease; 25 participated in the dose escalation and 16 patients with RCC or melanoma were enrolled in expansion cohorts. The dose escalation phase evaluated 0.1, 0.3, 1.0, 3.0, and 10 mg/kg of varlilumab given over 90 min without prophylactic premedication.

Varlilumab exposure was dose-dependent and linear across dosing groups. T cell saturation occurred with doses of 1 mg/kg and higher.

Dose escalation did not identify a maximum tolerated dose, and patients received a median of 4 doses.

One patient discontinued treatment due to grade 3 asymptomatic hyponatremia that occurred 14 days after the last dose of varlilumab and spontaneously resolved. Other grade 3 adverse events — which did not lead to discontinuation — were decreased appetite and decreased lymphocyte count.

Most treatment-related toxicities were grade 1 or 2 in severity and included fatigue, rash, nausea, and diarrhea. Infusion reactions occurred in 3 patients, 2 of which were prevented with premedication prior to subsequent dosing.

Antitumor activity was noted among 9 patients. A patient with RCC experienced tumor regression and stable disease for at least 3.9 years. Four patients with RCC, 3 with melanoma, and 1 with CRC experienced disease stabilization for over 3 months.

RELATED: Phase 1 Trial of Palbociclib With Chemotherapy for Solid Tumors

According to the authors, these findings “provide proof of concept and a rationale for further study in combination with immunotherapies and traditional therapies.” Additional studies of varlilumab are ongoing.

Reference

  1. Burris HA, Infante JR, Ansell SM, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. J Clin Oncol. 2017 May 2. doi: 10.1200/JCO.2016.70.1508 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters